Ocular Drug Delivery News
-
Otsuka Collaborates With ShapeTX To Develop Novel AAV Gene Therapies For Ocular Diseases
9/7/2023
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announce a multi-target collaboration to develop intravitreally-delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional targets and tissue types.
-
Sirio Launches Pharma Targeted Softgels At CPHI Barcelona
8/25/2023
Sirio Europe (SIRIO) – the leading global nutraceuticals contract development and manufacturing organization (CDMO) – will launch two new softgels targeted at customers who look to innovate in the consumer health space at CPHI Barcelona
-
Bora Pharmaceuticals Unveils Eye-Opening New Facility For Ophthalmic Manufacturing
7/31/2023
Bora Pharmaceuticals, a leading contract development and manufacturing organization (CDMO), is pleased to announce the opening of a new state-of-the-art facility in Taoyuan City, Taiwan.
-
Grifols Enters Into Global Collaboration And Licensing Agreement With Selagine To Develop Immunoglobulin Eye Drops To Treat Dry Eye Disease
3/6/2023
Grifols one of the world’s leading producers of plasma-derived medicines, today announced a global collaboration and licensing agreement with Selagine Inc, a company focused on developing novel therapeutics for ocular diseases, to treat dry eye disease (DED) with immunoglobulin eye drops.